[Translated article] Patient-reported outcome measures for assessing atopic dermatitis in clinical practice.

IF 1 Q4 PHARMACOLOGY & PHARMACY FARMACIA HOSPITALARIA Pub Date : 2024-09-18 DOI:10.1016/j.farma.2024.08.004
Gabriel Mercadal-Orfila, Carlos Seguí-Solanes, Nuria Rudi-Sola, Maria Eugenia Escriva-Sancho, Rosa Taberner-Ferrer
{"title":"[Translated article] Patient-reported outcome measures for assessing atopic dermatitis in clinical practice.","authors":"Gabriel Mercadal-Orfila, Carlos Seguí-Solanes, Nuria Rudi-Sola, Maria Eugenia Escriva-Sancho, Rosa Taberner-Ferrer","doi":"10.1016/j.farma.2024.08.004","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis is a chronic skin condition that affects up to 20% of children and 10% of adults worldwide. Due to the high burden of dermatological signs and symptoms, atopic dermatitis has a significant impact on the quality of life of patients and their families. In the absence of objective measures to accurately assess severity and symptom burden, patient-reported outcome measures are essential to monitor the impact and progression of the disease, as well as the efficacy of treatments. Although there are currently no standardised guidelines for their use in clinical practice, there are some initiatives, such as the Harmonise Outcome Measures for Eczema and Vivir con Dermatitis Atópica, that can provide guidance. As healthcare systems move toward value-based healthcare models, patient-reported measures are becoming increasingly important for incorporating the patient perspective and improving the quality of healthcare services. The use of these measures can help monitor disease activity and guide treatment decisions. This article discusses the impact of atopic dermatitis and describes the patient-reported outcome measures commonly used in atopic dermatitis and the recommendations of the initiatives that have selected a core set of measures to best assess atopic dermatitis in clinical practice. Considering the recommendations of these initiatives and based on our experience in clinical practice, we propose the use of the Dermatology Life Quality Index to assess the impact of the disease on quality of life, the Patient-Oriented Eczema Measure to assess symptom severity, and the Numerical Rating Scale or the Visual Analogue Scale to measure itch intensity. To systematise the administration of these measures and to integrate them into hospital information systems and medical records, we emphasise the importance of telemedicine platforms that allow the electronic administration of these instruments.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA HOSPITALARIA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.farma.2024.08.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Atopic dermatitis is a chronic skin condition that affects up to 20% of children and 10% of adults worldwide. Due to the high burden of dermatological signs and symptoms, atopic dermatitis has a significant impact on the quality of life of patients and their families. In the absence of objective measures to accurately assess severity and symptom burden, patient-reported outcome measures are essential to monitor the impact and progression of the disease, as well as the efficacy of treatments. Although there are currently no standardised guidelines for their use in clinical practice, there are some initiatives, such as the Harmonise Outcome Measures for Eczema and Vivir con Dermatitis Atópica, that can provide guidance. As healthcare systems move toward value-based healthcare models, patient-reported measures are becoming increasingly important for incorporating the patient perspective and improving the quality of healthcare services. The use of these measures can help monitor disease activity and guide treatment decisions. This article discusses the impact of atopic dermatitis and describes the patient-reported outcome measures commonly used in atopic dermatitis and the recommendations of the initiatives that have selected a core set of measures to best assess atopic dermatitis in clinical practice. Considering the recommendations of these initiatives and based on our experience in clinical practice, we propose the use of the Dermatology Life Quality Index to assess the impact of the disease on quality of life, the Patient-Oriented Eczema Measure to assess symptom severity, and the Numerical Rating Scale or the Visual Analogue Scale to measure itch intensity. To systematise the administration of these measures and to integrate them into hospital information systems and medical records, we emphasise the importance of telemedicine platforms that allow the electronic administration of these instruments.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[译文]在临床实践中评估特应性皮炎的患者报告结果测量法。
特应性皮炎是一种慢性皮肤病,全世界有多达 20% 的儿童和 10% 的成年人患有这种疾病。由于特应性皮炎的皮肤症状和体征较多,因此对患者及其家人的生活质量有很大影响。由于缺乏准确评估严重程度和症状负担的客观测量方法,患者报告的结果测量对于监测疾病的影响和进展以及治疗效果至关重要。虽然目前还没有在临床实践中使用这些指标的标准化指南,但一些倡议,如 "湿疹结果衡量标准协调 "和 "湿疹患者的生活",可以提供指导。随着医疗保健系统向以价值为基础的医疗保健模式转变,患者报告的衡量标准对于纳入患者观点和提高医疗保健服务质量变得越来越重要。使用这些指标有助于监测疾病活动并指导治疗决策。本文讨论了特应性皮炎的影响,并介绍了特应性皮炎常用的患者报告结果测量方法,以及为在临床实践中更好地评估特应性皮炎而选择了一套核心测量方法的倡议建议。考虑到这些倡议的建议,并根据我们在临床实践中的经验,我们建议使用皮肤科生活质量指数(Dermatology Life Quality Index)来评估疾病对生活质量的影响,使用患者导向湿疹测量法(Patient-Oriented Eczema Measure)来评估症状的严重程度,使用数字评分量表(Numerical Rating Scale)或视觉模拟量表(Visual Analogue Scale)来测量瘙痒的强度。为了使这些测量方法的实施系统化,并将其纳入医院信息系统和医疗记录,我们强调了远程医疗平台的重要性,该平台允许以电子方式实施这些工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
FARMACIA HOSPITALARIA
FARMACIA HOSPITALARIA PHARMACOLOGY & PHARMACY-
CiteScore
1.90
自引率
21.40%
发文量
46
审稿时长
37 days
期刊介绍: Una gran revista para acceder a los mejores artículos originales y revisiones de la farmacoterapia actual. Además, es Órgano de expresión científica de la Sociedad Española de Farmacia Hospitalaria, y está indexada en Index Medicus/Medline, EMBASE/Excerpta Médica, Alert, Internacional Pharmaceutical Abstracts y SCOPUS.
期刊最新文献
Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in the therapy of hemophilia A in clinical practice. Prospective observational follow-up study of psychoactive drugs treatment initiated in the intensive care unit. Protocol for the adaptation and consensus of the Community Pharmacy Survey on Patient Safety Culture to hospital pharmacy in Spain. Toxicity of the FOLFOX-6 regimen, with or without 5-fluorouracil bolus, in metastatic colorectal cancer. A quarter of a century of the VIH-SEFH group: Transforming care, facing challenges and reaffirming commitment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1